A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Alzheimer's Disease

Treatments: Drug: PF-03654746; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01028911

A8801016

Details and patient eligibility

About

This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.

Enrollment: 9 patients

Sex: All

Ages: 55 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Probable Alzheimer's disease
• Mini Mental State Examination score 18-26 inclusive
• Aged 55-85

Exclusion criteria

• Dementia other than Alzheimer's disease
• Clinically significant cardiovascular disease in the past 6 months prior to screening
• Creatinine clearance <30 mL/min

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

9 participants in 2 patient groups, including a placebo group

PF-03654746

Experimental group

Treatment:

Drug: PF-03654746

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo